Oxyntomodulin long-acting - Pharmsynthez/Xenetic Biosciences

Drug Profile

Oxyntomodulin long-acting - Pharmsynthez/Xenetic Biosciences

Alternative Names: Oxyntolong; PSA-oxyntomodulin

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmsynthez; Xenetic Biosciences
  • Developer Pharmsynthez
  • Class Anorectics; Antihyperglycaemics; Gastrointestinal hormones; Obesity therapies; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 27 Mar 2017 Xenetic Biosciences has patent protection for PolyXen™ platform technology in Europe, Asia and North America, including USA
  • 11 Jul 2016 Phase-II clinical trials in Obesity in Russia (SC) (Xenetic Biosciences pipeline, July 2016)
  • 11 Jul 2016 Phase-II clinical trials in Type-2 diabetes mellitus in Russia (SC) (Xenetic Biosciences pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top